With lean Agency reviewer bandwidth and fast-moving policies, companies can’t afford stalled submissions, or fragmented vendors and handoffs.
FDA Partners delivers one integrated team to align regulatory strategy, validate clinical evidence, and audit quality systems under one roof, so you stay ready.
We integrate deep interdisciplinary expertise across industry, FDA, and academia to provide strategic regulatory and scientific guidance.
We’ve secured first-ever Alzheimer’s Breakthrough Device Designation, earned marketing authorizations for pioneering AI/ML tools, and authored FDA guidances and training still used today. We don’t just follow the cutting edge; we set it.
Unlike large CROs and other advisory firms that hand your project to junior associates, FDA Partners provides direct, daily access to former FDA leaders and subject matter experts.

We maximize the value of the pre-submission (Q-Sub) and pre-IND processes, and the Breakthrough Device Designation (BDD)/Accelerated Review Programs, by developing the FDA strategy and then executing end-to-end: building Target Product Profiles (TPPs) and Data Development Plans (DDPs), preparing the submission package, leading high-impact “Sprint” discussions and FDA meetings, and driving favorable FDA outcomes, documented in finalized meeting minutes.

FDA-ready eSTAR submissions with clear predicate/novelty strategy and robust substantial equivalence rationales built to avoid preventable deficiencies and keep review timelines on track.

Smartly complete value-added activities to minimize FDA regulatory requirements and clinical burdens to secure marketing approvals.

Bridging international development data (Europe/Asia) to meet stringent FDA requirements.

FDA-ready eSTAR submissions with clear predicate/novelty strategy and robust substantial equivalence rationales built to avoid preventable deficiencies and keep review timelines on track.

We design "totality of evidence" narratives, leveraging any existing Real-World Data/Evidence (RWD/RWE) to satisfy modern evidentiary standards.

End-to-end study design, data management, and site monitoring for clinical studies.

We don't just help you prepare; we help you survive the audit. We conduct rigorous mock inspections (on-site + virtual) and readiness assessments for Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP), to ensure your data and sites are compliant.

We build and remediate QMSR and ISO 13485 conforming systems tailored to your stage, ensuring you are scalable and audit-ready without unnecessary burden.
For international biopharma companies entering the U.S. market, we offer targeted pathway and study design support, including regulatory/clinical strategy, RWD/RWE framing, and GCP/GMP readiness - to enable efficient progress today and scalable success over the long term.
Partner with the experts who sat on the other side of the table. Contact us to schedule an introductory strategy session with our experts.
Copyright © 2026 FDA Partners - All Rights Reserved.
FDA Partners - contact@fda-partners.com